Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries.
Equitable access to medicine around the world is a challenge in the healthcare industry, which has been gaining in attention over the last few years. To address this challenge, over a year ago, eight of the biggest pharma companies came together in the field of oncology to look to provide treatment to some of the world’s poorest countries in terms of healthcare.
The Access to Oncology Medicines (ATOM) coalition was formed in May of 2022, by Novartis, AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead, Roche, Sanofi, and Teva. Since the initial formation, other leaders in oncology therapeutic development and manufacturing have added their names, including Amgen, Eli Lilly, Merck, Pfizer, and Thermo Fisher Scientific.
In these nations, consisting of some of the world’s most vulnerable people, oncology treatment is limited or completely unavailable.
Now, even more steps are being taken to ensure treatment can be provided in low- to middle-income countries.
The Medicines Patent Pool (MPP), founded in 2010 by Unitaid and backed by the United Nations has signed four drugmakers to produce generics of a cancer therapeutic. This adds to their portfolio of agreements for HIV antiretrovirals, hepatitis C antiretrovirals, COVID-19 treatments, among others.
The drugmakers will be tasked to produce versions of Novartis’ myeloid leukemia blockbuster Tasigna (nilotinib), even though it is still under a patent in the US. The companies, BrightGene, based in Indonesia, and Dr. Reddy’s, Eugia and Hetero, all based in India, will be working to manufacture the generics in Egypt, Guatamala, Morocco, Pakistan, the Philippines, and Tunisia and distribute to 44 territories.
“We have seen great gains in cancer survival in the richest countries over the last decade, however, the benefit of our innovation is not reaching everyone,” Lutz Hagemann, President of Global Health and Sustainability at Novartis, stated recently.
“Through public-private partnerships, we aim to address barriers to healthcare and expand access to innovative treatment solutions for the long-term for as many people as possible.”
Revamped EU drug regulations increase accessibility but limit innovation?
The European Union’s pharmaceutical industry could face a serious change in operations after Brussels published a proposal for the revamping of certain laws governing the industry. Read more...
These efforts to increase global access to cancer treatments comes after the stark realisation that less developed countries were not receiving the level of cancer care for their populations that they should. In 2020 the WHO released figures stating that 3.5 million new cancer cases were diagnosed every year in low- and middle-income countries, responsible for 2.3 million premature deaths. A figure which is predicted to increase to 4 million deaths in the next 20 years without drastic intervention.
“We are determined to show that voluntary licensing is a truly impactful way of delivering affordable treatments to tackle the ever-rising burden of cancer in low- and middle-income countries,” Charles Gore, Director of the MPP stated.
Source: Fierce Pharma. Generics to Novartis' leukemia drug Tasigna to reach poor countries under 4 MPP licenses. [Date accessed 23/06/2023]. www.fiercepharma.com/pharma/novartis-signs-4-companies-provide-generic-versions-leukemia-drug-tasigna-poor-countries
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Biden's $2 billion Biotech Boost
President Biden issues executive order to bolster U.S. biomanufacturing sector.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance